Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction

Kei Sakamoto, Afshan McCarthy, Darrin Smith, Kevin A. Green, D. Grahame Hardie, Alan Ashworth, Dario R. Alessi

    Research output: Contribution to journalArticle

    396 Citations (Scopus)

    Abstract

    Recent studies indicate that the LKB1 tumour suppressor protein kinase is the major 'upstream' activator of the energy sensor AMP-activated protein kinase (AMPK). We have used mice in which LKB1 is expressed at only 10% of the normal levels in muscle and most other tissues, or that lack LKB1 entirely in skeletal muscle. Muscle expressing only 10% of the normal level of LKB1 had significantly reduced phosphorylation and activation of AMPK2. In LKB1-lacking muscle, the basal activity of the AMPK2 isoform was greatly reduced and was not increased by the AMP-mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR), by the antidiabetic drug phenformin, or by muscle contraction. Moreover, phosphorylation of acetyl CoA carboxylase-2, a downstream target of AMPK, was profoundly reduced. Glucose uptake stimulated by AICAR or muscle contraction, but not by insulin, was inhibited in the absence of LKB1. Contraction increased the AMP:ATP ratio to a greater extent in LKB1-deficient muscles than in LKB1-expressing muscles. These studies establish the importance of LKB1 in regulating AMPK activity and cellular energy levels in response to contraction and phenformin.
    Original languageEnglish
    Pages (from-to)1810-1820
    Number of pages11
    JournalThe EMBO Journal
    Volume24
    Issue number10
    DOIs
    Publication statusPublished - May 2005

    Fingerprint

    AMP-Activated Protein Kinases
    Muscle
    Skeletal Muscle
    Chemical activation
    Glucose
    Muscles
    Phenformin
    Adenosine Monophosphate
    Muscle Contraction
    Phosphorylation
    Tumor Suppressor Proteins
    Acetyl-CoA Carboxylase
    Hypoglycemic Agents
    Protein Kinases
    Protein Isoforms
    Adenosine Triphosphate
    Insulin
    Electron energy levels
    Tissue
    Sensors

    Keywords

    • AMP-activated protein kinase
    • Glucose transport
    • LKB1
    • Phenformin
    • Skeletal muscle

    Cite this

    Sakamoto, Kei ; McCarthy, Afshan ; Smith, Darrin ; Green, Kevin A. ; Hardie, D. Grahame ; Ashworth, Alan ; Alessi, Dario R. / Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. In: The EMBO Journal. 2005 ; Vol. 24, No. 10. pp. 1810-1820.
    @article{827ad978cb2345e6bbb9a3e863f3c773,
    title = "Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction",
    abstract = "Recent studies indicate that the LKB1 tumour suppressor protein kinase is the major 'upstream' activator of the energy sensor AMP-activated protein kinase (AMPK). We have used mice in which LKB1 is expressed at only 10{\%} of the normal levels in muscle and most other tissues, or that lack LKB1 entirely in skeletal muscle. Muscle expressing only 10{\%} of the normal level of LKB1 had significantly reduced phosphorylation and activation of AMPK2. In LKB1-lacking muscle, the basal activity of the AMPK2 isoform was greatly reduced and was not increased by the AMP-mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR), by the antidiabetic drug phenformin, or by muscle contraction. Moreover, phosphorylation of acetyl CoA carboxylase-2, a downstream target of AMPK, was profoundly reduced. Glucose uptake stimulated by AICAR or muscle contraction, but not by insulin, was inhibited in the absence of LKB1. Contraction increased the AMP:ATP ratio to a greater extent in LKB1-deficient muscles than in LKB1-expressing muscles. These studies establish the importance of LKB1 in regulating AMPK activity and cellular energy levels in response to contraction and phenformin.",
    keywords = "AMP-activated protein kinase, Glucose transport, LKB1, Phenformin, Skeletal muscle",
    author = "Kei Sakamoto and Afshan McCarthy and Darrin Smith and Green, {Kevin A.} and Hardie, {D. Grahame} and Alan Ashworth and Alessi, {Dario R.}",
    note = "dc.publisher: Nature Publishing Group",
    year = "2005",
    month = "5",
    doi = "10.1038/sj.emboj.7600667",
    language = "English",
    volume = "24",
    pages = "1810--1820",
    journal = "EMBO Journal",
    issn = "0261-4189",
    publisher = "EMBO Press",
    number = "10",

    }

    Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. / Sakamoto, Kei; McCarthy, Afshan; Smith, Darrin; Green, Kevin A.; Hardie, D. Grahame; Ashworth, Alan; Alessi, Dario R.

    In: The EMBO Journal, Vol. 24, No. 10, 05.2005, p. 1810-1820.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction

    AU - Sakamoto, Kei

    AU - McCarthy, Afshan

    AU - Smith, Darrin

    AU - Green, Kevin A.

    AU - Hardie, D. Grahame

    AU - Ashworth, Alan

    AU - Alessi, Dario R.

    N1 - dc.publisher: Nature Publishing Group

    PY - 2005/5

    Y1 - 2005/5

    N2 - Recent studies indicate that the LKB1 tumour suppressor protein kinase is the major 'upstream' activator of the energy sensor AMP-activated protein kinase (AMPK). We have used mice in which LKB1 is expressed at only 10% of the normal levels in muscle and most other tissues, or that lack LKB1 entirely in skeletal muscle. Muscle expressing only 10% of the normal level of LKB1 had significantly reduced phosphorylation and activation of AMPK2. In LKB1-lacking muscle, the basal activity of the AMPK2 isoform was greatly reduced and was not increased by the AMP-mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR), by the antidiabetic drug phenformin, or by muscle contraction. Moreover, phosphorylation of acetyl CoA carboxylase-2, a downstream target of AMPK, was profoundly reduced. Glucose uptake stimulated by AICAR or muscle contraction, but not by insulin, was inhibited in the absence of LKB1. Contraction increased the AMP:ATP ratio to a greater extent in LKB1-deficient muscles than in LKB1-expressing muscles. These studies establish the importance of LKB1 in regulating AMPK activity and cellular energy levels in response to contraction and phenformin.

    AB - Recent studies indicate that the LKB1 tumour suppressor protein kinase is the major 'upstream' activator of the energy sensor AMP-activated protein kinase (AMPK). We have used mice in which LKB1 is expressed at only 10% of the normal levels in muscle and most other tissues, or that lack LKB1 entirely in skeletal muscle. Muscle expressing only 10% of the normal level of LKB1 had significantly reduced phosphorylation and activation of AMPK2. In LKB1-lacking muscle, the basal activity of the AMPK2 isoform was greatly reduced and was not increased by the AMP-mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR), by the antidiabetic drug phenformin, or by muscle contraction. Moreover, phosphorylation of acetyl CoA carboxylase-2, a downstream target of AMPK, was profoundly reduced. Glucose uptake stimulated by AICAR or muscle contraction, but not by insulin, was inhibited in the absence of LKB1. Contraction increased the AMP:ATP ratio to a greater extent in LKB1-deficient muscles than in LKB1-expressing muscles. These studies establish the importance of LKB1 in regulating AMPK activity and cellular energy levels in response to contraction and phenformin.

    KW - AMP-activated protein kinase

    KW - Glucose transport

    KW - LKB1

    KW - Phenformin

    KW - Skeletal muscle

    U2 - 10.1038/sj.emboj.7600667

    DO - 10.1038/sj.emboj.7600667

    M3 - Article

    VL - 24

    SP - 1810

    EP - 1820

    JO - EMBO Journal

    JF - EMBO Journal

    SN - 0261-4189

    IS - 10

    ER -